OpGen, Inc. (OPGN): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a company tackles the global challenge of infectious diseases using cutting-edge technology? OpGen, Inc., a precision medicine company, is doing just that by harnessing molecular diagnostics and informatics. But how exactly does OpGen work, who owns it, what's their mission, and most importantly, how does it make money in the competitive healthcare market, especially considering its recent 1-for-10 reverse stock split announced on May 16, 2024? Keep reading to find out!

OpGen, Inc. (OPGN) History

OpGen's Founding Timeline

Year established

The company was established in 2001.

Original location

The company was originally located in Cambridge, MA.

Founding team members

While specific names of all founding team members are not readily available in the provided context, OpGen was founded by a team of entrepreneurs and scientists focused on developing molecular diagnostic tools to combat antibiotic resistance.

Initial capital/funding

Details regarding the precise initial capital or funding amounts are not available in the provided search results.

OpGen's Evolution Milestones

OpGen's Transformative Moments

OpGen's journey has been marked by strategic decisions and technological advancements that have shaped its trajectory in the field of molecular diagnostics and antibiotic resistance:

• Strategic Acquisitions: The acquisition of AdvanDx in 2009 significantly broadened OpGen's product line and market presence, integrating rapid diagnostic tests for bloodstream infections into its portfolio.
• Public Offering: The 2015 IPO was a pivotal moment, providing OpGen with the financial resources needed to scale its operations, invest in research and development, and commercialize its diagnostic solutions on a broader scale.
• Technological Innovation: The development and launch of the Acuitas AMR Gene Panel marked a significant advancement in OpGen's capabilities, offering clinicians a powerful tool for identifying antimicrobial resistance genes and guiding treatment decisions.
• Regulatory Milestones: FDA clearance for key products, such as the Acuitas AMR Gene Panel, validated OpGen's technology and opened up new opportunities for adoption in clinical settings, driving revenue growth and market expansion.
• Platform Focus: A strategic emphasis on the Unyvero platform signaled a commitment to comprehensive testing solutions, positioning OpGen as a leader in syndromic testing and precision medicine.

These transformative moments reflect OpGen's evolution from a startup to a publicly traded company focused on combating antibiotic resistance through innovative molecular diagnostic solutions. To gain more insights into who is investing in the company, consider reading: Exploring OpGen, Inc. (OPGN) Investor Profile: Who’s Buying and Why?

OpGen, Inc. (OPGN) Ownership Structure

OpGen, Inc. has a mixed ownership structure, comprising institutional investors, individual shareholders, and company insiders.

OpGen, Inc.'s Current Status

OpGen, Inc. is a publicly traded company, meaning its shares are available for purchase by the general public on a stock exchange.

OpGen, Inc.'s Ownership Breakdown

OpGen's ownership is distributed among various types of shareholders. As the data from 2024 fiscal year shows, the percentages held by different shareholders can vary due to market activity and trading.

OpGen, Inc.'s Leadership

The leadership team is responsible for the strategic direction and operational management of the company. Here are some key aspects of OpGen, Inc.'s leadership:

• Oliver Schacht, PhD: Serves as the President and CEO.
• Timothy C. Venter: Is the Senior Vice President and Chief Financial Officer.

For further insights into OpGen, Inc. and its investors, check out: Exploring OpGen, Inc. (OPGN) Investor Profile: Who’s Buying and Why?

OpGen, Inc. (OPGN) Mission and Values

OpGen, Inc. is committed to delivering precision medicine solutions that aid in combating infectious diseases. The company focuses on providing actionable information to improve patient outcomes and reduce the spread of infections.

OpGen's Core Purpose

Official mission statement

OpGen's mission statement is to:

• Develop, commercialize, and market innovative molecular diagnostic solutions helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by multi-drug resistant microorganisms.

Vision statement

While a specific, publicly declared vision statement for OpGen is not readily available, the company's actions and statements suggest a vision focused on:

• Becoming a leader in providing rapid, accurate, and actionable diagnostic information to combat infectious diseases.
• Improving patient outcomes through precision medicine approaches.
• Contributing to the reduction of healthcare costs associated with managing infectious diseases.

Company slogan/tagline

OpGen's tagline or slogan is not explicitly publicized. However, considering their focus, a fitting tagline might emphasize:

• Speed and accuracy in diagnostics.
• Combating antimicrobial resistance.
• Improving patient care through informed decisions.

To gain more in-depth insights into OpGen's financial standing, explore Breaking Down OpGen, Inc. (OPGN) Financial Health: Key Insights for Investors.

OpGen, Inc. (OPGN) How It Works

OpGen, Inc. is a precision medicine company that focuses on developing and commercializing molecular diagnostic tests to help combat multi-drug resistant organisms. These tests enable healthcare providers to rapidly identify infectious agents and guide antibiotic therapy, improving patient outcomes and reducing the spread of antibiotic resistance.

OpGen, Inc.'s Product/Service Portfolio

OpGen, Inc.'s Operational Framework

OpGen operates through a combination of direct sales and distribution partnerships to reach its target markets. The company's operational framework includes:

• Test Development and Manufacturing: OpGen develops its molecular diagnostic tests using its proprietary technologies and manufactures them in its facilities.
• Sales and Marketing: The company employs a direct sales force and collaborates with distributors to market and sell its products to hospitals, reference laboratories, and other healthcare providers.
• Data Analysis and Reporting: OpGen provides data analysis and reporting services through its Acuitas Lighthouse software platform, helping customers track and manage antimicrobial resistance.
• Customer Support: OpGen offers technical support and training to its customers to ensure proper use of its products and interpretation of results.

OpGen, Inc.'s Strategic Advantages

OpGen's strategic advantages include:

• Proprietary Technology: OpGen's Acuitas platform offers rapid and comprehensive detection of antimicrobial resistance genes, providing a competitive edge over traditional methods.
• Data Analytics Capabilities: The Acuitas Lighthouse software provides valuable insights into antimicrobial resistance trends, supporting infection control and antibiotic stewardship programs.
• Focus on Unmet Needs: OpGen addresses the critical need for rapid and accurate diagnostics to combat antibiotic resistance, a growing global health threat.

To gain further insights into the values that guide the company, explore Mission Statement, Vision, & Core Values of OpGen, Inc. (OPGN).

OpGen, Inc. (OPGN) How It Makes Money

OpGen, Inc. primarily generates revenue through the sale of its molecular diagnostic tests and services, which help healthcare providers identify infectious diseases and guide antibiotic treatment decisions.

OpGen, Inc.'s Revenue Breakdown

As of the fiscal year 2024, the precise percentage breakdown of OpGen's revenue streams is not available in the provided search results. To accurately assess the revenue composition, a review of OpGen's latest financial reports is essential. However, based on their business activities, revenue streams can be categorized as follows:

OpGen, Inc.'s Business Economics

The business economics of OpGen, Inc. are influenced by several factors:

• Pricing Strategy: The pricing of molecular diagnostic tests is critical. It must balance market competitiveness, the cost of goods sold (COGS), and the value provided to healthcare providers through improved patient outcomes and reduced healthcare costs.
• Reimbursement Landscape: Reimbursement rates from insurance companies and government healthcare programs significantly impact revenue. Favorable reimbursement policies are essential for test adoption.
• Cost Structure: High R&D expenses are typical in the molecular diagnostics industry. Efficient cost management in manufacturing, sales, and marketing is crucial for profitability.
• Market Access: Successful market penetration depends on regulatory approvals, strategic partnerships with hospitals and labs, and effective sales and marketing efforts.

OpGen, Inc.'s Financial Performance

Analyzing OpGen, Inc.'s financial performance requires a review of key metrics as of the fiscal year 2024. Because specific financial data is not available in the search results, a general discussion of relevant metrics follows:

• Revenue Growth: This indicates the rate at which the company's sales are increasing. It reflects market demand and the effectiveness of the sales strategy.
• Gross Margin: This measures the profitability of the company's products after deducting the cost of goods sold. A higher gross margin indicates efficient production and pricing strategies.
• Operating Expenses: These include R&D, sales, and administrative costs. Monitoring these expenses is essential to ensure they are aligned with revenue growth.
• Net Income/Loss: This is the bottom-line profit or loss after all expenses are deducted. It reflects the overall financial health of the company.
• Cash Flow: Monitoring cash flow from operations, investing, and financing activities is crucial for assessing liquidity and financial stability.

To gain a comprehensive understanding of OpGen's financial health, consult their Mission Statement, Vision, & Core Values of OpGen, Inc. (OPGN). and review their latest financial reports and investor presentations.

OpGen, Inc. (OPGN) Market Position & Future Outlook

OpGen, Inc. is navigating a dynamic market landscape, focusing on innovative solutions for combating antimicrobial resistance and hospital-acquired infections. While specific market share data is limited, the company's future hinges on strategic execution and capitalizing on emerging opportunities within the infectious disease diagnostics sector.

Competitive Landscape

Opportunities & Challenges

Industry Position

OpGen's industry position can be further understood through the following points:

• Focus on Antimicrobial Resistance: OpGen specializes in providing diagnostic solutions specifically targeted at combating antimicrobial resistance (AMR). This specialization allows them to cater to a critical and growing need in healthcare.
• Innovation in Molecular Diagnostics: OpGen leverages molecular diagnostics to offer precise and rapid detection of infectious agents and antibiotic resistance markers. This technology enables healthcare providers to make informed decisions quickly, improving patient outcomes and reducing the spread of infections.
• Strategic Collaborations and Partnerships: OpGen actively seeks collaborations and partnerships to expand its market reach, enhance its product offerings, and accelerate innovation. These alliances can provide access to new technologies, markets, and expertise, strengthening OpGen's competitive position.

To learn more about OpGen's guiding principles, visit: Mission Statement, Vision, & Core Values of OpGen, Inc. (OPGN).